Daily Sepsis Research Analysis

In 223 ICU patients with clinically suspected sepsis, both plasma and whole-blood ddPCR detected substantially more pathogens than blood culture alone and provided microbiological support in blood culture-negative cases adjudicated as definite sepsis. Overall performance was similar between the two specimen types, but whole-blood ddPCR detected Candida more frequently than plasma ddPCR, suggesting a potentially important advantage for fungal sepsis.

Impact: This study directly evaluates a clinically deployable molecular diagnostic strategy in a prospective multicenter ICU cohort. Its finding that whole-blood ddPCR may improve Candida detection addresses a major limitation of culture-based diagnosis in high-risk sepsis patients.

Clinical Implications: Paired plasma and whole-blood ddPCR may be considered as adjuncts to blood culture when rapid pathogen identification is essential, particularly in suspected fungal sepsis. The findings do not justify replacing blood culture or initiating therapy solely on the basis of ddPCR without clinical interpretation.

Future Directions: Larger prospective studies should evaluate fungal sepsis specifically, determine the incremental diagnostic value and turnaround-time advantages of whole-blood ddPCR, and test whether ddPCR-guided antimicrobial decisions improve mortality, time to effective therapy, and antimicrobial stewardship.

Using biventricular pressure-volume measurements in a porcine endotoxic shock model, the study found that effective arterial elastance, end-diastolic volume, and end-systolic elastance explained most of the variation in left ventricular ejection fraction, with loading variables predominating. Ejection fraction remained within a relatively narrow range despite major changes in preload, afterload, and contractility, indicating that EF can conceal clinically important hemodynamic changes during shock.

Impact: The study challenges the common interpretation of ejection fraction as a direct surrogate for myocardial contractility in septic shock. Its pressure-volume framework provides a mechanistic basis for more cautious interpretation of ventricular function and treatment response.

Clinical Implications: Clinicians should avoid interpreting an unchanged or mildly reduced EF as proof of preserved or impaired intrinsic contractility during septic shock. Assessment should incorporate loading conditions, pressure-volume relationships, ventricular volumes, and load-independent contractility indices when available.

Future Directions: Clinical studies should test whether pressure-volume-informed assessment, advanced echocardiographic load-independent indices, or serial volumetric measurements improve phenotyping and treatment decisions in septic cardiomyopathy and right ventricular failure.

This Cochrane review included 11 randomized clinical trials involving 1,273 adults with cirrhosis and bacterial infections. Albumin showed uncertain effects on mortality and kidney impairment compared with no intervention or other intravenous fluids; it may reduce septic shock compared with other fluids, but the evidence was low certainty, and albumin may increase serious adverse events.

Impact: This review provides a rigorous synthesis of a widely used adjunctive therapy and emphasizes that apparent benefits of albumin are not supported by high-certainty evidence. Its conclusions are directly relevant to fluid selection, resource allocation, and avoidance of routine treatment based on assumption rather than evidence.

Clinical Implications: Routine albumin administration for cirrhotic patients with bacterial infection cannot be justified by current high-quality evidence. Clinicians should individualize use according to infection site, hemodynamic status, renal function, volume status, adverse-event risk, and local protocols while recognizing the substantial uncertainty in the evidence.

Future Directions: Future randomized trials should use standardized albumin dosing and clinically relevant stratification by infection site, infection severity, cirrhosis stage, renal dysfunction, and hemodynamic phenotype. Trials should also report quality of life, long-term outcomes, serious adverse events, and cost-effectiveness.